Evidence-Based Prevention and Treatment for Gastric Diseases_Chinese Journal of Evidence-Based Medicine

Authors：

CHEN Shiyao , LIU Tianshu , PENG Chunyan , WANG Jiyao

Department of Gastroenterology; Zhong Shan Hospital and Clinical Epidemiology/ Evidenced-based Medicine Center; Fu Dan University; Shanghai 200032; China;

Corresponding author：

Keywords：

Chronic gastritis; Peptic ulcer; Gastric carcinoma; Helicobacter pylori; Evidenced-based medicine; Clinical evidence

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

To explain how to treat common gastric diseases like chronic gastritis, peptic ulcer, functional dyspepsia and gastric oesophageal reflux disease (GORD) based on evidence-based medicine. Through this paper, we try to help readers find and use clinical evidence to solve clinical problems.

Citation： CHEN Shiyao,LIU Tianshu,PENG Chunyan,WANG Jiyao. Evidence-Based Prevention and Treatment for Gastric Diseases. Chinese Journal of Evidence-Based Medicine, 2004, 04(10): 723-729. doi: Copy

1.	［1］Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM. Association of H. Pylori infection with gastric carcinoma: a meta analysis[J]. World J Gastroenterol, 2001; 7(5): 801-805.
2.	［2］Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis[J]. Am J Gastroenterol, 1999; 94(9): 2 373-2 379.
3.	［3］Malfertheiner P, Megraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G; European Helicobacter pylori Study Group(EHPSG). Current concepts in the management of Helicobater pylori imfection-the Maastricht 2-2000 consensus report[J]. Aliment Pharmacol Ther, 2002; 16(2): 167-180.
4.	［4］Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD, Mera R. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy[J]. J Natl Cancer Inst, 2000; 92(23): 1 881-1 888.
5.	［5］Uemura N, Mukai T, Okamato S,Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer[J]. Cancer Epidemiol Biomarkers Prev, 1997; 6(8): 639-642.
6.	［6］Uemura N,Okamato S,Yamamoto S. Effects of Helicobacter pylori eradication on the background gastric mucosal the patients after endoscopic mucosal resection of early gastric cancer[J]. Gastroenterology, 2000; 118: A502.
7.	［7］Wong B, Lam SK, Wong W. Eradicating Helicobacter pylori infection in general population prevents gastric cancer:a 7-year prospective randomized placebo controlled study[J]. Gastroenterology, 2002; 122: A588.
8.	［8］Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2 751 patients[J]. Aliment Pharmacol Ther, 2003; 17(1): 99-109.
9.	［9］Hassan C, De Francesco V, Zullo A, Scaccianoce G, Piglionica D, Ierardi E, Panella C, Morini S. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy[J]. Aliment Pharmacol Ther, 2003; 18(6): 641-646.
10.	［10］Redstone HA, Barrowman N, Veldhuyzen Van Zanten SJ. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials[J]. Aliment Pharmacol Ther, 2001; 15(9): 1 291-1 299.
11.	［11］Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D. Pharmacological interventions for non-ulcer dyspepsia[CD/M]. Issue 1. 2003. Cochrane Database Syst Rev.
12.	［12］Moayyedi P, Soo S, Deeks J. Forman D, Mason J, Innes M, Delaney B. Systematic review and economic evaluation of H. Pylori eradication for non-ulcer dyspepsia[J]. BMJ, 2000; 321(7262): 659-664.
13.	［13］Chiba N, Grra CJD, Wilkinson JM, Hunt RH. Speed of Healing and symptom relief in grade II to IV Gastroesopgageal ruflux disease: a meta-analysis[J]. Gastroenterology, 1997; 112(6): 1 798-1 810.
14.	［14］Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastro-oesophageal reflux disease in general practice[J]. BMJ, 2001; 322(7282): 344-347.
15.	［15］Bardhan KD. Intermitten and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease[J]. Am J Gastroenterol, 2003; 98(suppl): S40-S48.
16.	［16］Asian-Pacific Consensus Conference on GORD[C]. Asia pacific digestive week 2003, 2730 September 2003, Singapore.
17.	［17］Graham DY. The changing epidemiology of GORD: geography and Helicobacter pylori[J]. Am J Gastroenterol, 2003; 98(7): 1 462-1 470.
18.	［18］Raghunath A, Hungin AP, Woff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review[J]. BMJ, 2003; 326 (7 392): 73.
19.	［19］Cremonini F, Caro SD, Delgado-Aros S, Sepulveda A, Gasbarrini G, Gasbarrini A, Camilleri M. Meta-analysis: The Relationship Between Helicobacter pylori Infection and Gastro-Oesophageal Reflux Disease[J]. Aliment Pharmacol Ther, 2003; 18(3): 279-289.

1. ［1］Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM. Association of H. Pylori infection with gastric carcinoma: a meta analysis[J]. World J Gastroenterol, 2001; 7(5): 801-805.
2. ［2］Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis[J]. Am J Gastroenterol, 1999; 94(9): 2 373-2 379.
3. ［3］Malfertheiner P, Megraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G; European Helicobacter pylori Study Group(EHPSG). Current concepts in the management of Helicobater pylori imfection-the Maastricht 2-2000 consensus report[J]. Aliment Pharmacol Ther, 2002; 16(2): 167-180.
4. ［4］Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD, Mera R. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy[J]. J Natl Cancer Inst, 2000; 92(23): 1 881-1 888.
5. ［5］Uemura N, Mukai T, Okamato S,Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer[J]. Cancer Epidemiol Biomarkers Prev, 1997; 6(8): 639-642.
6. ［6］Uemura N,Okamato S,Yamamoto S. Effects of Helicobacter pylori eradication on the background gastric mucosal the patients after endoscopic mucosal resection of early gastric cancer[J]. Gastroenterology, 2000; 118: A502.
7. ［7］Wong B, Lam SK, Wong W. Eradicating Helicobacter pylori infection in general population prevents gastric cancer:a 7-year prospective randomized placebo controlled study[J]. Gastroenterology, 2002; 122: A588.
8. ［8］Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2 751 patients[J]. Aliment Pharmacol Ther, 2003; 17(1): 99-109.
9. ［9］Hassan C, De Francesco V, Zullo A, Scaccianoce G, Piglionica D, Ierardi E, Panella C, Morini S. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy[J]. Aliment Pharmacol Ther, 2003; 18(6): 641-646.
10. ［10］Redstone HA, Barrowman N, Veldhuyzen Van Zanten SJ. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials[J]. Aliment Pharmacol Ther, 2001; 15(9): 1 291-1 299.
11. ［11］Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D. Pharmacological interventions for non-ulcer dyspepsia[CD/M]. Issue 1. 2003. Cochrane Database Syst Rev.
12. ［12］Moayyedi P, Soo S, Deeks J. Forman D, Mason J, Innes M, Delaney B. Systematic review and economic evaluation of H. Pylori eradication for non-ulcer dyspepsia[J]. BMJ, 2000; 321(7262): 659-664.
13. ［13］Chiba N, Grra CJD, Wilkinson JM, Hunt RH. Speed of Healing and symptom relief in grade II to IV Gastroesopgageal ruflux disease: a meta-analysis[J]. Gastroenterology, 1997; 112(6): 1 798-1 810.
14. ［14］Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastro-oesophageal reflux disease in general practice[J]. BMJ, 2001; 322(7282): 344-347.
15. ［15］Bardhan KD. Intermitten and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease[J]. Am J Gastroenterol, 2003; 98(suppl): S40-S48.
16. ［16］Asian-Pacific Consensus Conference on GORD[C]. Asia pacific digestive week 2003, 2730 September 2003, Singapore.
17. ［17］Graham DY. The changing epidemiology of GORD: geography and Helicobacter pylori[J]. Am J Gastroenterol, 2003; 98(7): 1 462-1 470.
18. ［18］Raghunath A, Hungin AP, Woff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review[J]. BMJ, 2003; 326 (7 392): 73.
19. ［19］Cremonini F, Caro SD, Delgado-Aros S, Sepulveda A, Gasbarrini G, Gasbarrini A, Camilleri M. Meta-analysis: The Relationship Between Helicobacter pylori Infection and Gastro-Oesophageal Reflux Disease[J]. Aliment Pharmacol Ther, 2003; 18(3): 279-289.

Chinese Journal of Evidence-Based Medicine

Evidence-Based Prevention and Treatment for Gastric Diseases

Abstract Full text Figures/Tables Video References Cited by

Format

Content